or Try an Advanced Search...

    Technical Analysis for MNPR - Monopar Therapeutics Inc.

    Grade Last Price % Change Price Change
    A 26.91 7.73% 1.93
    MNPR closed up 7.73 percent on Wednesday, January 15, 2025, on approximately normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical MNPR trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Support Bullish 7.73%
    Wide Bands Range Expansion 7.73%
    NR7 Range Contraction 4.75%
    Narrow Range Bar Range Contraction 4.75%
    Inside Day Range Contraction 4.75%
    Older End-of-Day Signals for MNPR ...

       Recent Intraday Alerts

    Alert Time
    Possible Pocket Pivot about 5 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Outside Day about 9 hours ago
    Up 5% about 9 hours ago
    Up 3% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    MNPR Chart by TradingView

    Profile

    Monopar Therapeutics is a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for advanced soft tissue sarcoma; and a late-stage preclinical antibody MNPR-101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Radiation Therapy Sarcoma Head And Neck Cancer Soft Tissue Sarcoma Mucositis Radiotherapy Oral Mucositis Otorhinolaryngology

    Is MNPR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 15 Monopar Therapeutics files to sell 882,761 shares of common stock for holders
    Jan 2 MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
    Dec 31 These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025
    Dec 26 What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
    Dec 23 Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
    Dec 20 Monopar Therapeutics announces pricing of $40M public offering of common stock
    Dec 20 Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
    Dec 5 Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
    Dec 3 Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
    Nov 26 Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus
    See more MNPR news...

    Comments

    Indicators

    Indicator Value
    52 Week High 38.5
    52 Week Low 1.545
    Average Volume 99,457
    200-Day Moving Average 8.65
    50-Day Moving Average 21.90
    20-Day Moving Average 25.00
    10-Day Moving Average 24.34
    Average True Range 2.49
    RSI (14) 59.18
    ADX 24.56
    +DI 23.66
    -DI 16.95
    Chandelier Exit (Long, 3 ATRs) 24.72
    Chandelier Exit (Short, 3 ATRs) 28.48
    Upper Bollinger Bands 29.48
    Lower Bollinger Band 20.52
    Percent B (%b) 0.71
    BandWidth 35.84
    MACD Line 1.00
    MACD Signal Line 1.02
    MACD Histogram -0.0194
    Fundamentals Value
    Market Cap 400.05 Million
    Num Shares 14.9 Million
    EPS -0.72
    Price-to-Earnings (P/E) Ratio -37.38
    Price-to-Sales 0.00
    Price-to-Book 0.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 31.28
    Resistance 3 (R3) 30.79 28.85 30.55
    Resistance 2 (R2) 28.85 27.74 29.09 30.30
    Resistance 1 (R1) 27.88 27.05 28.37 28.37 30.06
    Pivot Point 25.94 25.94 26.18 26.18 25.94
    Support 1 (S1) 24.97 24.83 25.46 25.46 23.76
    Support 2 (S2) 23.03 24.14 23.27 23.52
    Support 3 (S3) 22.06 23.03 23.27
    Support 4 (S4) 22.55